|
||||||||
Company Profile | ||||||||
Chairman | CEO | Spokesperson | Tel | Address | Date of Listing (Regular) | |||
---|---|---|---|---|---|---|---|---|
HUANG, KUO-LUNG | HUANG, KUO-LUNG | HUANG, KUO-LUNG | 0281777020 | Box 309, Ugland HouseGrand Cayman, KY1-1104, Cayman Islands | 2014/01/17 | |||
Agent for litigious and non-litigious matters |
Tel of Agent for litigious and non-litigious matters |
Address of Agent for litigious and non-litigious matters |
||||||
HUANG, KUO-LUNG | 0281777020 | 7F., NO. 138, XINMING RD., NEIHU DIST., TAIPEI CITY 11470, TAIWAN (R.O.C.) | ||||||
Industry | Main Business | |||||||
Biotechnology and Medical Care | Founded in 2001, TaiGen Biotechnology (TaiGen Taiwan) is a leading research- based and product-driven biotechnology company in Taiwan with a wholly-owned subsidiary in Beijing, China. In 2008, TaiGen Taiwan completed a share swap with TaiGen Biopharmaceuticals Holdings Limited (TaiGen Cayman), and has become a fully owned subsidiary of TaiGen Cayman. TaiGen's current pipeline includes therapeutics for infectious diseases, diabetic complications and cancer for the worldwide market. Nemonoxacin is a novel broad-spectrum non-fluorinated quinolone antibiotic under development for respiratory infections. In addition to nemonoxacin, TaiGen has two NCEs in clinical development under IND with US FDA: TG-0054, a chemokine receptor antagonist for stem cell transplantation and chemosensitization and TG-2349, a HCV protease inhibitor for treatment of chronic hepatitis infectio. Both TG- 0054 and TG-2349 are currently in clinical trials in patients in the US. |
Market Information ( 2024/05/03 ) | |||||||||||
Shr. Vol. | Highest | Lowest | Closed | Change | Transaction | TurnOver(%) | long margin balance (1,000shr.) |
Short margin balance (1,000shr.) |
|||
---|---|---|---|---|---|---|---|---|---|---|---|
2398.368 | 15.30 | 15.00 | 15.00 | -0.15 | 1086 | .00 | 8,628 | 0 | |||
Trading method | Fun purchase price or securities pneeded on T day |
Announcement of Irregularity (2024/05/06) |
TPEx measures adopted (2024/05/06) |
With warrants | Can be shorted or margined? | Detail | |||||
Normal | N | N | N | Y | Y | Today | History |
Financial Reports | |||||
---|---|---|---|---|---|
Cash Flows | Items | ||||
Amount (NT$ thousand) |
|||||
Cash flows from operating activities | |||||
Cash flows from investing activities | |||||
Cash flows from financing activities | |||||
Balance Sheets |
Current assets | ||||
Non-current assets | |||||
Total assets | |||||
Current liabilities | |||||
Non-current liabilities | |||||
Total liabilities | |||||
Share capital | |||||
Capital surplus | |||||
Retained earnings | |||||
Other equity interest | |||||
Treasury shares | |||||
Total equity attributable to owners of parent | |||||
Non-controlling interests | |||||
Total equity | |||||
Book Value per share(NT$) | |||||
Comprehensive Income | Operating revenue | ||||
Operating costs | |||||
Gross profit from operations | |||||
Operating expenses | |||||
Net other income (expenses) | |||||
Net operating income | |||||
Non-operating income and expenses | |||||
Profit before tax | |||||
Tax expense | |||||
Profit from continuing operations | |||||
Profit from discontinued operations | |||||
Profit | |||||
Other comprehensive income | |||||
Comprehensive income | |||||
Basic earnings per share |
Auditor's report on latest financial statements: auditor's report: |
More detail:MOPS。 |
Foreign issuers’ information is disclosed in consolidated statements. |